Loading institutional data...
Loading institutional data...
Institutional distribution: ownership decreased -1.91% quarter-over-quarter.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Solve the discounted cash flow backwards, then stress-test the assumptions.
This company doesn't have positive free cash flow, so a reverse DCF can't be run.
Top 15 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
2/6 of the 9 checks — 3 couldn't be scored (see above), so the score is out of the 6 with data.
Insufficient balance-sheet detail (needs retained earnings, working capital, equity).
Needs granular two-year detail (receivables, PP&E, D&A, SG&A) — not fully reported.
Cash-conversion data unavailable. Lower/negative accruals = higher quality (Sloan).
Coverage data unavailable.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned on -$10M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Operating income fell despite reinvestment — a warning on capital productivity. Current ROIC on all capital: -210%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
$1M of principal comes due within a year. Scheduled principal only (excludes interest & revolver draws). As of 2021-09-30 (10-Q).
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Thin coverage — earnings barely cover interest. Interest last disclosed in FY2020 (no longer broken out).
Cash vs short-term debt unavailable.
Short-term / long-term split not separately reported.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
EOD close · as of 2026-08-05
No standout strengths flagged.
Where each multiple sits in its own 14-yr range · 0th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Operating leverage needs meaningful revenue change.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 87.7 | 77.1 | 77.2 | 88.4 | 58.0 | 88.4 | 100.0 | — |
| Gross Profit | 12.3 | 22.9 | 22.8 | 11.6 | 42.0 | 11.6 | — | — |
| R&D | 128.8 | 175.4 | 415.2 | 993.1 | 837.2 | 394.7 | 4375.9 | — |
| SG&A | 56.3 | 75.2 | 183.5 | 607.7 | 705.3 | 534.0 | 3531.8 | — |
| Operating Income | -172.8 | -227.7 | -787.7 | -1589.2 | -1500.6 | -917.1 | -7907.7 | — |
| Income Tax | — | -13.2 | -35.5 | -104.9 | -121.7 | -210.6 | -342.7 | — |
| Net Income | -169.8 | -202.1 | -749.7 | -1522.7 | -1454.1 | -726.7 | -6953.1 | — |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on SNGX: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
EOD close · as of 2026-08-05 · 15d old
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $119K 100.0% | $839K 100.0% | $949K 100.0% | $824K 100.0% | $2.4M 100.0% | $4.6M 100.0% | $5.2M 100.0% | $5.4M 100.0% | $10.4M 100.0% |
| Cost of Revenue | — | $119K 100.0% | $742K 88.4% | $551K 58.0% | $729K 88.4% | $1.8M 77.2% | $3.6M 77.1% | $4.6M 87.7% | $4.3M 79.3% | $8.4M 80.7% |
| Gross Profit | — | — | $97K 11.6% | $398K 42.0% | $96K 11.6% | $538K 22.8% | $1.1M 22.9% | $644K 12.3% | $1.1M 20.7% | $2.0M 19.3% |
| Research & Development | $7.5M | $5.2M 4375.9% | $3.3M 394.7% | $7.9M 837.2% | $8.2M 993.1% | $9.8M 415.2% | $8.1M 175.4% | $6.8M 128.8% | $5.5M 101.4% | $4.3M 41.1% |
| Selling, General & Admin | $4.4M | $4.2M 3531.8% | $4.5M 534.0% | $6.7M 705.3% | $5.0M 607.7% | $4.3M 183.5% | $3.5M 75.2% | $3.0M 56.3% | $3.2M 59.1% | $3.4M 32.8% |
| Total Operating Expenses | $11.8M | $9.4M 7907.7% | $7.8M 928.7% | $14.6M 1542.5% | $13.2M 1600.8% | $19.1M 810.6% | $11.6M 250.6% | $9.7M 185.1% | $8.7M 160.4% | $7.7M 73.9% |
| Operating Income | -$11.8M | -$9.4M -7907.7% | -$7.7M -917.1% | -$14.2M -1500.6% | -$13.1M -1589.2% | -$18.6M -787.7% | -$10.5M -227.7% | -$9.1M -172.8% | -$7.6M -139.8% | -$5.7M -54.6% |
| Interest Expense | — | — | — | — | — | $34K 1.5% | — | — | — | — |
| Interest & Investment Income | — | — | — | — | — | — | $149K 3.2% | $159K 3.0% | — | — |
| Other Income (Expense), net | $258K | $764K 639.9% | -$211K -25.1% | -$714K -75.3% | -$317K -38.4% | $61K 2.6% | $575K 12.4% | $159K 3.0% | $30K 0.6% | $1.9M 18.5% |
| Pretax Income | -$11.6M | -$8.7M -7267.8% | -$7.9M -942.2% | -$15.0M -1575.8% | -$13.4M -1627.6% | -$18.5M -785.2% | -$10.0M -215.3% | -$8.9M -169.8% | -$7.6M -139.2% | -$3.8M -36.1% |
| Income Tax Expense | -$507K | -$409K -342.7% | -$1.8M -210.6% | -$1.2M -121.7% | -$865K -104.9% | -$837K -35.5% | -$611K -13.2% | — | -$417K -7.7% | -$530K -5.1% |
| Net Income | -$11.1M | -$8.3M -6953.1% | -$6.1M -726.7% | -$13.8M -1454.1% | -$12.6M -1522.7% | -$17.7M -749.7% | -$9.4M -202.1% | -$8.9M -169.8% | -$7.1M -131.6% | -$3.2M -31.1% |
| Per Share | ||||||||||
| EPS (Basic) | $-2.14 | $-4.98 | $-12.66 | $-4.81 | $-4.69 | $-0.64 | — | — | $-1.16 | $-0.93 |
| EPS (Diluted) | $-2.14 | $-4.98 | $-12.66 | $-4.81 | $-4.69 | $-0.64 | — | — | $-1.16 | $-1.34 |
| Weighted Avg Shares (Basic) | 5.2M | 1.7M | 485K | 2.9M | 2.7M | 27.5M | — | — | 6.1M | 3.5M |
| Weighted Avg Shares (Diluted) | 5.2M | 1.7M | 485K | 2.9M | 2.7M | 27.5M | — | — | 6.1M | 3.6M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Ranked against 1111 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| LLY | $1.05T | 51.0× | — | 16.1× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $679.0B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $620.1B | 23.4× | — | 6.6× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $435.4B | 104.3× | 31.4× | 7.1× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| UNH | $374.0B | 31.2× | 21.4× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| BDRX | $359.1B | — | — | — | — | — | — | — | — | — | 7 |
| MRK | $321.1B | 17.6× | — | 4.9× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| NVSEF | $289.9B | — | — | — | — | — | — | — | — | — | 2 |
| AZN | $250.4B | — | — | — | — | — | — | — | — | — | 1,248 |
| AMGN | $219.7B | 28.7× | 18.3× | 6.0× | 10.0% | 67.2% | 21.0% | 89.1% | 13.1% | 3.5× | 3,014 |
| TMO | $217.8B | 32.6× | 28.5× | 4.9× | 3.9% | — | 15.1% | 12.6% | 7.0% | 4.9× | 2,481 |
| ABT | $183.9B | 28.4× | 19.5× | 4.2× | 5.7% | 56.4% | 14.7% | 12.5% | 10.5% | 1.0× | 2,964 |
| GILD | $163.5B | 19.4× | 18.1× | 5.5× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| PFE | $146.7B | 19.0× | — | 2.3× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $141.1B | 39.5× | 29.3× | 5.7× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $133.2B | 47.7× | 36.6× | 13.2× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| SYK | $128.8B | 40.1× | 21.8× | 5.1× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| CVS | $126.0B | 71.3× | 12.7× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| VRTX | $123.1B | 31.6× | 26.9× | 10.3× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| MDT | $110.1B | 23.1× | 11.7× | 3.0× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| GLAXF | $106.9B | — | — | — | — | — | — | — | — | — | 5 |
| MCK | $102.7B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| SNYNF | $101.3B | — | — | — | — | — | — | — | — | — | 5 |
| HCA | $92.0B | 14.5× | — | 1.2× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $86.4B | 15.5× | 14.8× | 0.4× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| SNGX | $4M | — | — | — | — | — | — | -210% | -210% | — | 15 |
Peers = companies sharing SNGX's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.